← Leaderboards
Alan H. Beggs
Children'S Hospital Boston
$8,694,387
Attributed
$8,766,474
Total exposure
7
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.9M · FY2005–18$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
Funding mix
By agency
NIH$14,878,152 · 8
By mechanism
R01$7,095,012 · 2
U19$6,255,853 · 3
P50$1,118,694 · 1
P01$264,328 · 1
K02$144,265 · 1
Top collaborators
- Robert C. Green8 shared
Most similar at Children'S Hospital Boston
Same institution · by research overlap
- Louis M Kunkel$14,824,943
- Christopher Pierson$848,425
- Isaac S. Kohane$83,411,167
Others in their field
Top investigators on “Base”
- Sonia M Thomas · Research Triangle Institute$700,865,642
- David Heimbrook · Leidos Biomedical Research, Inc.$613,567,095
- David Divins · Consortium For Ocean Leadership, Inc$609,772,544
- Larry Arthur$521,411,998
- Leonard Freedman · Leidos Biomedical Research, Inc.$515,995,429
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$507,042,060
Research focus
BaseGeneticFamilyFutureDiagnosisZebrafishGenesMolecularLeadNeuromuscular DiseasesBirthGene MutationMutationMutation AnalysisSkeletal Muscle StructureGene TherapyFamily MemberPlayMuscleDesignCandidate Disease GenePhenotypeInfancyChildhood
Grant awards (38)
Genetic screening and therapies for nemaline myopathies$367,275
R01 · FY2018 · HD · contact PI
Genome Sequence Based Screening for Childhood Risk and Newborn Illness$250,000
U19 · FY2018 · HD
ConProject-001$108,168
U19 · FY2018 · HD
ConProject-002$36,007
U19 · FY2018 · HD
Genome Sequence-Based Screening for Childhood Risk and Newborn Illness$1,187,163
U19 · FY2017 · HD
Genes and Therapies for Centronuclear Myopathies$369,750
R01 · FY2017 · AR · contact PI
Genetic screening and therapies for nemaline myopathies$367,275
R01 · FY2017 · HD · contact PI
Genome Sequence-Based Screening for Childhood Risk and Newborn Illness$1,175,303
U19 · FY2016 · HD
Genes and Therapies for Centronuclear Myopathies$369,750
R01 · FY2016 · AR · contact PI
Genetic screening and therapies for nemaline myopathies$363,602
R01 · FY2016 · HD · contact PI
Genome Sequence-Based Screening for Childhood Risk and Newborn Illness$1,157,495
U19 · FY2015 · HD
Genes and Therapies for Centronuclear Myopathies$369,750
R01 · FY2015 · AR · contact PI
Genetic screening and therapies for nemaline myopathies$357,586
R01 · FY2015 · HD · contact PI
Genome Sequence-Based Screening for Childhood Risk and Newborn Illness$1,153,935
U19 · FY2014 · HD
Genes and Therapies for Centronuclear Myopathies$369,750
R01 · FY2014 · AR · contact PI
Genetic screening and therapies for nemaline myopathies$364,681
R01 · FY2014 · HD · contact PI
Genome Sequence-Based Screening for Childhood Risk and Newborn Illness$1,187,782
U19 · FY2013 · HD
Genes and Therapies for Centronuclear Myopathies$369,750
R01 · FY2013 · AR · contact PI
In Vivo Functions of Myotubularins and Therapy for Myotubular Myopathy$284,622
P50 · FY2011 · NS · contact PI
Alpha-actinins in normal and diseased muscle$350,261
R01 · FY2010 · AR · contact PI
In Vivo Functions of Myotubularins and Therapy for Myotubular Myopathy$268,590
P50 · FY2010 · NS · contact PI
Alpha-actinins in normal and diseased muscle$353,798
R01 · FY2009 · AR · contact PI
In Vivo Functions of Myotubularins and Therapy for Myotubular Myopathy$291,104
P50 · FY2009 · NS · contact PI
Alpha-actinins in normal and diseased muscle$353,798
R01 · FY2008 · AR · contact PI
In Vivo Functions of Myotubularins and Therapy for Myotubular Myopathy$274,378
P50 · FY2008 · NS · contact PI
Alpha-actinins in normal and diseased muscle$361,018
R01 · FY2007 · AR · contact PI
In Vivo Functions of Myotubularins and Therapy for Myotubular Myopathy$264,328
P01 · FY2007 · NS · contact PI
Alpha-actinins in normal and diseased muscle$371,800
R01 · FY2006 · AR · contact PI
SARCOMERIC PROTEINS IN NORMAL AND DISEASED MUSCLE$300,200
R01 · FY2005 · AR
SARCOMERIC PROTEINS IN NORMAL AND DISEASED MUSCLE$300,200
R01 · FY2004 · AR
SARCOMERIC PROTEINS IN NORMAL AND DISEASED MUSCLE$300,200
R01 · FY2003 · AR
SARCOMERIC PROTEINS IN NORMAL AND DISEASED MUSCLE$300,200
R01 · FY2002 · AR
GENE EXPRESSION % MUSCLE DEVELOPMENT IN MYOTUBULAR MYOPATHY$0
P01 · FY2002 · NS
SARCOMERIC PROTEINS IN NORMAL AND DISEASED MUSCLE$298,931
R01 · FY2001 · AR
ALPHA ACTININS IN NORMALS AND DISEASED MUSCLE$45,445
K02 · FY2001 · AR
GENE EXPRESSION % MUSCLE DEVELOPMENT IN MYOTUBULAR MYOPATHY$0
P01 · FY2001 · NS
ALPHA ACTININS IN NORMAL AND DISEASED MUSCLE$135,437
R01 · FY2000 · AR
ALPHA ACTININS IN NORMALS AND DISEASED MUSCLE$98,820
K02 · FY2000 · AR